Indian Drug maker Dr. Datsons Labs has received the proposal to supply the Artemisinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs will be making a significant deal though there is a minimum pricing that the company will be working on.
The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipea & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.
Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: